70,233 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC acquired 70,233 Sarepta Therapeutics shares worth approximately $1.27 million, giving it a 0.07% stake. Institutional investors and hedge funds collectively own 86.68% of the company.
• Sarepta reported quarterly EPS of $0.64, beating the $0.22 consensus, while revenue of $401.25 million exceeded expectations but declined 34.3% year over year. Shares opened at $21.03, up 0.8%.
• Analyst sentiment is mixed, with nine Buy, six Hold, and five Sell ratings; the stock has an overall “Hold” consensus and an average price target of $25.06.

Hsbc Holdings PLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 70,233 shares of the biotechnology company's stock, valued at approximately $1,267,000. Hsbc Holdings PLC owned 0.07% of Sarepta Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRPT. AQR Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 214.2% in the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company's stock valued at $344,000 after acquiring an additional 3,671 shares during the period. Great Lakes Advisors LLC bought a new position in Sarepta Therapeutics during the first quarter worth $224,000. Guggenheim Capital LLC raised its stake in Sarepta Therapeutics by 33.5% during the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company's stock valued at $783,000 after purchasing an additional 11,497 shares during the last quarter. First Trust Advisors LP raised its stake in Sarepta Therapeutics by 59.2% during the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company's stock valued at $10,731,000 after purchasing an additional 233,391 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in Sarepta Therapeutics by 7.1% in the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company's stock valued at $1,972,000 after purchasing an additional 7,665 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Trading Up 0.8%

Shares of Sarepta Therapeutics stock opened at $21.03 on Tuesday. The firm has a market capitalization of $2.22 billion, a PE ratio of -7.25, a price-to-earnings-growth ratio of 0.31 and a beta of 0.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62. The company's fifty day moving average price is $17.79 and its two-hundred day moving average price is $18.34. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analysts' expectations of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business's revenue was down 34.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.02 EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on SRPT. HC Wainwright restated a "buy" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Wolfe Research upgraded shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price for the company in a research note on Thursday, July 9th. Piper Sandler decreased their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating on the stock in a research report on Thursday, July 9th. Wall Street Zen lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Weiss Ratings downgraded Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research report on Wednesday, August 19th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has an average rating of "Hold" and a consensus price target of $25.06.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source